Acarix ABACIXF 47 Market Cap is $32.60 Mil as of Jun. 25, 2026. GuruFocus rates ACIXF with a GF Score™ of 47/100 and a GF Value™ of $0.02 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 866 Medical Devices & Instruments companies, Acarix AB ranks worse than 68.82% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Acarix AB's share price for the quarter that ended in Mar. 2026 was $0.029. Acarix AB's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 1,187.50 Mil. Therefore, Acarix AB's market cap for the quarter that ended in Mar. 2026 was $34.44 Mil.
Acarix AB's quarterly market cap
declined
from Sep. 2025 ($42.12 Mil) to Dec. 2025 ($35.47 Mil) and
declined
from Dec. 2025 ($35.47 Mil) to Mar. 2026 ($34.44 Mil).
Acarix AB's annual market cap
increased
from Dec. 2023 ($10.32 Mil) to Dec. 2024 ($29.23 Mil) and
increased
from Dec. 2024 ($29.23 Mil) to Dec. 2025 ($35.47 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Acarix AB's Enterprise Value for Today is $29.50 Mil.
Acarix AB (OTCPK:ACIXF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Acarix AB Market Cap Related Terms
Acarix AB Market Cap Historical Data
* Premium members only.
The historical data trend for Acarix AB's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Acarix AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acarix AB Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Acarix AB's Market Cap distribution charts can be found below:
* The bar in red indicates where Acarix AB's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Acarix AB's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acarix AB (ACIXF) has a Market Cap of $32.60 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Acarix AB and its competitors. According to the industry distribution chart, Acarix AB ranks #596 out of 866 companies in the Medical Devices & Instruments industry, placing it in the top 68.8%.
Is Acarix AB's Market Cap too high?
Acarix AB's current Market Cap is $32.60 Mil. The Medical Devices & Instruments industry median Market Cap is 122.09. Acarix AB's value of $32.60 Mil is 73.3% below this industry median. Based on the distribution chart, Acarix AB ranks #596 out of 866 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Acarix AB has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Acarix AB's Market Cap compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Acarix AB ranks #596 out of 866 companies for Market Cap. This places Acarix AB in the lower half of its industry. The industry median Market Cap is 122.09. Acarix AB's value of $32.60 Mil is 73.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 122.09, based on 866 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acarix AB's current Market Cap of $32.60 Mil is 73.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Acarix AB and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 122.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acarix AB's current Market Cap is $32.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acarix AB stock overvalued right now?
Based on GuruFocus' analysis, Acarix AB (ACIXF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.03 — trading 45% above its estimated fair value. The current Market Cap is $32.60 Mil and 73.3% below the Medical Devices & Instruments industry median of 122.09. Acarix AB's overall GF Score™ is 47/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Acarix AB (ACIXF), the current Market Cap is $32.60 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acarix AB (ACIXF) Overvalued in 2026?
Based on GuruFocus' analysis, Acarix AB stock appears to be overvalued.
The current stock price of $0.03 is trading 45% above its estimated GF Value™ of $0.02.
GuruFocus considers Acarix AB to be Significantly Overvalued.
Key valuation signals for ACIXF:
Market Cap: $32.60 Mil
GF Value™: $0.02 vs. price of $0.03 (45% above fair value)
Industry Position: 73.3% below the Medical Devices & Instruments median (#596 of 866)
No single metric tells the full story. See the ACIXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). Its CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. Acarix recommends the CADScor System as a first-line diagnostic tool that uses sensitive acoustics and computational processing to analyze coronary blood flow to rule out coronary artery disease (CAD), with a majority certainty at the point of care. Geographically, the company generates maximum revenue from the United States, and the rest from Germany, Sweden, Iraq, and other regions.
47GF Score
Get the complete analysis for ACIXF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACIXF has been successfully added to your 
